Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
New Understanding and Treatment Advances in Itch
Description
The talk reviews major advances in understanding and treating itch, emphasizing that old simplistic models—itch with or without rash, heavy reliance on labs, and the idea that unclear itch was psychogenic—are outdated. Itch is now understood as a complex neuroimmune process involving skin barrier dysfunction, nerves, and immune signaling, with overlapping causes rather than a single category such as immunologic, neuropathic, or xerotic itch. The speaker highlights that modern therapies target multiple pathways, including IL-4, IL-13, IL-31, histamine receptors, and KIT, and notes emerging bispecific and conjugate approaches. He argues that antihistamines are no longer central to the story and that dermatologists should focus on long-term efficacy data, not just rapid symptom relief, because chronic itch requires sustained control. Overall, the message is that itch should be treated as a meaningful disease in its own right, with many new options available and even more on the way.
Conclusions
- Chronic itch is now best understood as a neuroimmune condition rather than a simple rash-versus-no-rash problem.
- The old assumption that unexplained itch is psychogenic or primarily an allergy/histamine issue is outdated.
- Itch often arises from overlapping immunologic, neuropathic, and barrier-related mechanisms rather than a single cause.
- Modern therapies validate the new itch framework because targeting cytokines, nerves, and mast-cell pathways can relieve itch.
- Fast itch relief is possible, but the more important clinical goal is durable long-term control.
- Several dermatologic treatments show sustained itch reduction over weeks to months, supporting long-term efficacy as the key benchmark.
- Itch may function as a distinct disease process even when it occurs alongside conditions like atopic dermatitis, prurigo nodularis, renal disease, or cholestatic disease.
- The next wave of treatments will likely involve multi-target biologics, bispecific antibodies, and pathway-specific agents that address both inflammation and itch signaling.
- Shao, Yixin & Wang, Duoqin & Zhu, Yiqi & Xiao, Zijing & Jin, Taiyu & Peng, Lisi & Shen, Yanyun & Tang, Hui. (2023). Molecular mechanisms of pruritus in prurigo nodularis. Frontiers in Immunology. 14. 10.3389/fimmu.2023.1301817.#10.3389/fimmu.2023.1301817
- Legat FJ et al.
- Irvine AD et al.
- Silverberg JI et al.